九价人乳头瘤病毒疫苗对相关疾病及根治性治疗的效力:与历史安慰剂人群的比较
该分析基于三项国际随机双盲研究,将九价HPV疫苗试验中7106名接种者与历史qHPV疫苗研究中8812名安慰剂受种者比较。在接种前14种HPV型别阴性女性中,九价HPV疫苗对9种疫苗型别相关高级别宫颈疾病和宫颈手术的效力分别为98.2%(95%CI 93.6-99.7)和97.8%(95%CI 93.4-99.4)。
要点
- 接种前14种HPV型别阴性女性中,九价HPV疫苗对9种型别相关高级别宫颈疾病效力98.2%。
- 同一人群中对9种型别相关宫颈手术的效力为97.8%。
- 九价HPV疫苗未预防基线已检出疫苗型别相关疾病,但显著减少其他疫苗型别相关宫颈、外阴和阴道疾病。
核心结论
- 有效实施九价HPV疫苗可能大幅降低HPV相关疾病及相关医疗操作的负担。
研究设计与样本
- 三项国际随机双盲研究采用相同方法学;九价HPV疫苗研究(NCT00543543)中7106名女性接种九价HPV疫苗、7109名女性接种四价HPV疫苗。
- 历史四价HPV疫苗研究FUTURE I(NCT00092521)和II(NCT00092534)中,基于相同入选标准,8810名女性接种四价HPV疫苗、8812名女性接种安慰剂。
- 定期进行宫颈细胞学检查,活检或根治性治疗标本评估HPV DNA。
主要发现
- 接种前14种HPV型别阴性女性中,9种HPV型别相关高级别宫颈疾病发生例数九价HPV疫苗组n=2例 vs 安慰剂组n=141例。
- 接种前14种HPV型别阴性女性中,9种HPV型别相关宫颈手术发生例数九价HPV疫苗组n=3例 vs 安慰剂组n=170例。
- 上述高级别宫颈疾病和宫颈手术分别减少98.2%(95%CI 93.6-99.7)和97.8%(95%CI 93.4-99.4)。
- 九价HPV疫苗未预防基线检出的疫苗HPV型别相关疾病,但显著减少其他疫苗HPV型别相关的宫颈、外阴和阴道疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries related to all nine vaccine components was assessed compared with a historic placebo population. This was not assessed in the 9vHPV vaccine efficacy trial since the trial was quadrivalent HPV (qHPV) vaccine-controlled, efficacy was measured for the five HPV types covered only by 9vHPV vaccine (HPV31/33/45/52/58), but not the four types covered by both vaccines (HPV6/11/16/18). METHODS: Three international, randomized, double-blind studies were conducted using the same methodology. In the 9vHPV vaccine study (NCT00543543), 7106 and 7109 women received 9vHPV or qHPV vaccine, respectively. In the historic qHPV vaccine studies (FUTURE I [NCT00092521] and II [NCT00092534]), 8810 and 8812 women received qHPV vaccine or placebo, respectively, based on the same eligibility criteria. Cervical cytological testing was performed regularly. Biopsy or definitive therapy specimens were assessed for HPV DNA. RESULTS: Among women negative for 14 HPV types prior to vaccination, incidence of high-grade cervical disease (9vHPV, n = 2 cases; placebo, n = 141 cases) and cervical surgery (9vHPV, n = 3 cases; placebo, n = 170 cases) related to the nine HPV types was reduced by 98.2% (95% confidence interval [CI], 93.6-99.7) and 97.8% (95% CI, 93.4-99.4), respectively. The 9vHPV vaccine did not prevent disease related to vaccine HPV types detected at baseline, but significantly reduced cervical, vulvar, and vaginal diseases related to other vaccine HPV types. CONCLUSIONS: Effective implementation of the 9vHPV vaccine may substantially reduce the burden of HPV-related diseases and related medical procedures. TRIAL REGISTRATIONS: clinicaltrials.gov: NCT00543543, NCT00092521, NCT00092534.
引用
- Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019. PMID: 30982556. doi:10.1016/j.ygyno.2019.03.253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。